Caron Harvey

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Jean Abraham, Karen Pinilla, Alimu Dayimu et al. · Nature · 2024 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial

Jean Abraham, Lenka Oplustil O’Connor, Louise Grybowicz et al. · Nature Communications · 2025 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.

Helena Earl, Anne-Laure Vallier, Wendi Qian et al. · Journal of Clinical Oncology · 2017 · 12 citations

Medicine, Oncology, Pharmacology +9

Abstract P3-10-05: Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients

Karen Pinilla, Emma McMurtry, Anne-Laure Vallier et al. · Cancer Research · 2020 · 10 citations

Medicine, Oncology, Pharmacology +14